Ileana Pina is a Cardiology physician affiliated with Thomas Jefferson University. OpenAlex indexes 24 publications with 2,656 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
925 Chestnut St
Philadelphia, PA 191074216
Telephone
215-955-0899Provider last certified this registry record 5 May 2022.
Clinical trials
- Deployment of American Heart Association Heart Failure Protocols and Content Within the Intel® Health Guide System
Sponsor: American Heart Association
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim International GmbHProgram year20254 payments$21,088openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20256 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.1%Beta blocker14.9%Metoprolol Succinate73%Carvedilol15%Bisoprolol Fumarate12%Part D<11 patientsAngiotensin receptor blocker (ARB)14.6%Candesartan Cilexetil81%Valsartan19%Part D<11 patients+ 11 more classes in this area
Metabolism & gastrointestinal
10.9%SGLT2 inhibitor10.9%Farxiga61%Jardiance39%Part D≥22 patientsBlood & clotting
8.7%Factor Xa inhibitor6%Eliquis84%Xarelto17%Part D<11 patientsP2Y12 inhibitor1.7%Clopidogrel100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1998–2002 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
David Whellan, MD
Thomas Jefferson University
Jesse Roman, MD
Thomas Jefferson University
Stephen Silberstein, MD
Thomas Jefferson University
David Cognetti, MD
Thomas Jefferson University
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”